- |||||||||| teriflunomide / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Teriflunomide Male Transmission Study (clinicaltrials.gov) - Jan 2, 2019 P=N/A, N=20, Completed, Recruiting --> Completed | N=40 --> 20 | Trial completion date: Dec 2017 --> Sep 2018 | Trial primary completion date: Oct 2017 --> Aug 2018
- |||||||||| Trial completion, Video: Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 21, 2018
P=N/A, N=31, Completed, N=220 --> 50 | Trial completion date: Apr 2019 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2019 --> Dec 2018; The required data was obtained and there was no need to collect further data Active, not recruiting --> Completed
- |||||||||| Kineret (anakinra) / SOBI
Enrollment change, Trial termination, Trial primary completion date: TRACK: Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes (clinicaltrials.gov) - Dec 14, 2018 P4, N=41, Terminated, N=178 --> 0 | Trial completion date: Dec 2020 --> Dec 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2020 --> Dec 2019 N=200 --> 41 | Recruiting --> Terminated | Trial primary completion date: Jul 2015 --> Dec 2017; Decision of the Sponsor for Early Benefits
- |||||||||| Betaseron (IFN-β-1b) / Bayer
Phase classification: Betaseron Pregnancy Registry (clinicaltrials.gov) - Dec 12, 2018 P=N/A, N=113, Completed, Active, not recruiting --> Terminated Phase classification: P4 --> P=N/A
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Trial completion date, Trial primary completion date: Niclosamide With Etanercept in Rheumatoid Arthritis (clinicaltrials.gov) - Dec 12, 2018 P1/2, N=110, Completed, Phase classification: P4 --> P=N/A Recruiting --> Completed | Trial completion date: Apr 2019 --> Dec 2018 | Trial primary completion date: Apr 2019 --> Aug 2018
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation (clinicaltrials.gov) - Dec 11, 2018
P=N/A, N=40, Completed, Recruiting --> Completed | Trial completion date: Apr 2019 --> Dec 2018 | Trial primary completion date: Apr 2019 --> Aug 2018 Recruiting --> Completed | N=600 --> 40 | Trial completion date: Dec 2020 --> Nov 2018 | Trial primary completion date: Apr 2020 --> Nov 2018
- |||||||||| tibulizumab (ZB-106) / Zura Bio
Trial completion: A Study of LY3090106 in Participants With Sj (clinicaltrials.gov) - Dec 11, 2018 P1, N=32, Completed, Recruiting --> Completed | N=600 --> 40 | Trial completion date: Dec 2020 --> Nov 2018 | Trial primary completion date: Apr 2020 --> Nov 2018 Active, not recruiting --> Completed
- |||||||||| Kinaction (masitinib) / AB Science
Trial completion date, Combination therapy: Masitinib in Refractory Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 10, 2018 P2b, N=324, Terminated, Phase classification: P2 --> P2a Trial completion date: Jun 2018 --> Sep 2016
- |||||||||| Kinaction (masitinib) / AB Science
Trial completion date, Trial primary completion date, Combination therapy: Masitinib in Refractory Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 6, 2018 P2b, N=324, Terminated, Active, not recruiting --> Completed Trial completion date: Dec 2015 --> Jun 2018 | Trial primary completion date: Dec 2013 --> Jun 2018
- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date: MESEMS: MEsenchymal StEm Cells for Multiple Sclerosis (clinicaltrials.gov) - Dec 3, 2018
P1/2, N=1, Terminated, Active, not recruiting --> Completed N=12 --> 1 | Trial completion date: May 2018 --> Dec 2017 | Recruiting --> Terminated | Trial primary completion date: May 2018 --> Dec 2017; inclusion default
- |||||||||| clindamycin phosphate / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: ESPERA: Therapeutic Management of Periodontitis and Clinical Manifestations of Rheumatoid Arthritis (clinicaltrials.gov) - Dec 3, 2018 P=N/A, N=22, Completed, N=12 --> 1 | Trial completion date: May 2018 --> Dec 2017 | Recruiting --> Terminated | Trial primary completion date: May 2018 --> Dec 2017; inclusion default Recruiting --> Completed | N=40 --> 22 | Trial completion date: Dec 2017 --> Nov 2016 | Trial primary completion date: Dec 2017 --> Nov 2016
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: NIMRA: Novel Imaging Markers for Rheumatoid Arthritis (clinicaltrials.gov) - Nov 30, 2018 P=N/A, N=30, Completed, Recruiting --> Completed | N=40 --> 22 | Trial completion date: Dec 2017 --> Nov 2016 | Trial primary completion date: Dec 2017 --> Nov 2016 Active, not recruiting --> Completed
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: A Task-oriented Circuit Training in Multiple Sclerosis (clinicaltrials.gov) - Nov 29, 2018
P=N/A, N=35, Completed, Active, not recruiting --> Completed Recruiting --> Completed | N=60 --> 35 | Trial primary completion date: Mar 2018 --> Oct 2018
- |||||||||| Trial completion date, Trial termination, Trial primary completion date: AIRSEP: Fatigue and Inspiratory Muscles Training in Patients With Multiple Sclerosis (clinicaltrials.gov) - Nov 23, 2018
P=N/A, N=46, Terminated, N=60 --> 0 | Trial completion date: Oct 2019 --> Nov 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2019 --> Nov 2018 Trial completion date: May 2019 --> Nov 2018 | Recruiting --> Terminated | Trial primary completion date: Aug 2018 --> May 2018; lack of recruitment
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: TMP001 in Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 21, 2018
P2a, N=9, Completed, Active, not recruiting --> Completed | Trial completion date: Jul 2019 --> Jul 2016 | Trial primary completion date: Oct 2018 --> Jul 2016 Recruiting --> Completed | N=55 --> 9 | Trial completion date: Dec 2017 --> Apr 2018 | Trial primary completion date: Dec 2017 --> Apr 2018
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: PAS:IDE: Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects (clinicaltrials.gov) - Nov 19, 2018
P=N/A, N=350, Completed, Active, not recruiting --> Completed | N=168 --> 70 | Initiation date: Jun 2016 --> Apr 2012 Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Aug 2017 | Trial primary completion date: Mar 2018 --> Jun 2017
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date: Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab (clinicaltrials.gov) - Nov 14, 2018 P=N/A, N=35, Completed, Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Mar 2018 --> Oct 2018
- |||||||||| Remicade (infliximab) / J&J
Trial completion date, Trial primary completion date: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Nov 2, 2018 P=N/A, N=140, Active, not recruiting, Not yet recruiting --> Completed | Trial completion date: Dec 2017 --> Oct 2018 Trial completion date: Dec 2019 --> Dec 2018 | Trial primary completion date: Dec 2019 --> Dec 2018
- |||||||||| Humalog pen (insulin lispro) / Eli Lilly
Trial completion: Environmental Effects Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 31, 2018 P=N/A, N=10, Completed, Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients (clinicaltrials.gov) - Oct 23, 2018
P=N/A, N=240, Completed, Recruiting --> Completed | N=100 --> 35 | Trial completion date: Mar 2019 --> Nov 2017 | Trial primary completion date: Mar 2018 --> Nov 2017 Recruiting --> Completed | Trial completion date: May 2018 --> Oct 2017 | Trial primary completion date: Nov 2017 --> Apr 2017
- |||||||||| PEC-Direct (PEC-01) / Vertex
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Safety and Tolerability Study of VC-02 (clinicaltrials.gov) - Oct 18, 2018 P1, N=3, Completed, N=413 --> 8 | Trial completion date: Jul 2018 --> Dec 2017 | Recruiting --> Terminated | Trial primary completion date: Jul 2018 --> Dec 2017; Planned recruitment target not reached Active, not recruiting --> Completed | N=15 --> 3 | Trial completion date: Jun 2018 --> Feb 2018 | Trial primary completion date: Jun 2018 --> Feb 2018
|